OTC Markets OTCPK - Delayed Quote USD

Novacyt S.A. (NVYTF)

0.5400
+0.0020
+(0.37%)
At close: June 5 at 8:00:00 PM EDT
Loading Chart for NVYTF
  • Previous Close 0.5380
  • Open 0.5000
  • Bid 0.6073 x 100000
  • Ask 0.6494 x 636700
  • Day's Range 0.5000 - 0.5000
  • 52 Week Range 0.5000 - 1.2500
  • Volume 91
  • Avg. Volume 1
  • Market Cap (intraday) 44.734M
  • Beta (5Y Monthly) 0.12
  • PE Ratio (TTM) --
  • EPS (TTM) -0.7400
  • Earnings Date Apr 30, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. It operates in the United Kingdom, France, Europe, the United States, the Asia Pacific, the Middle East, and Africa. The company was incorporated in 2006 and is based in Le Vésinet, France.

www.novacyt.com

234

Full Time Employees

December 31

Fiscal Year Ends

Recent News: NVYTF

View More

Performance Overview: NVYTF

Trailing total returns as of 6/10/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .

YTD Return

NVYTF
13.88%
CAC 40 (^FCHI)
5.59%

1-Year Return

NVYTF
8.00%
CAC 40 (^FCHI)
1.27%

3-Year Return

NVYTF
72.16%
CAC 40 (^FCHI)
25.96%

5-Year Return

NVYTF
95.29%
CAC 40 (^FCHI)
54.22%

Compare To: NVYTF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NVYTF

View More

Valuation Measures

Annual
As of 6/9/2025
  • Market Cap

    44.55M

  • Enterprise Value

    19.39M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.43

  • Price/Book (mrq)

    0.59

  • Enterprise Value/Revenue

    0.73

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -212.72%

  • Return on Assets (ttm)

    -10.19%

  • Return on Equity (ttm)

    -57.28%

  • Revenue (ttm)

    19.63M

  • Net Income Avi to Common (ttm)

    -38.7M

  • Diluted EPS (ttm)

    -0.7400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    30.64M

  • Total Debt/Equity (mrq)

    24.81%

  • Levered Free Cash Flow (ttm)

    -13.66M

Research Analysis: NVYTF

View More

Company Insights: NVYTF

Research Reports: NVYTF

View More

People Also Watch